As of 31 Dec 2025, 26 institutional investors reported holding $356,756,220 in principal (par value) of BRIDGEBIO PHARMA INC - NOTE 2.250% 2/0.
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | $356,756,220 | $403,368,426 | +$78,254,962 | 112.61% | 26 |
| 2025 Q3 | $627,523,074 | $621,164,871 | -$32,020,133 | 98.82% | 42 |
| 2025 Q2 | $677,587,704 | $702,102,373 | -$9,786,616 | 93.58% | 40 |
| 2025 Q1 | $692,365,423 | $625,022,166 | +$61,676,686 | 90.0% | 41 |
| 2024 Q4 | $627,730,524 | $538,661,074 | -$2,449,849 | 85.63% | 38 |
| 2024 Q3 | $632,466,339 | $531,505,798 | -$6,333,280 | 83.61% | 38 |
| 2024 Q2 | $641,592,339 | $515,193,030 | -$52,483,886 | 80.12% | 42 |
| 2024 Q1 | $705,552,289 | $610,874,985 | -$20,650,206,952 | 81.93% | 44 |
| 2023 Q4 | $738,008,709 | $628,227,229 | +$26,540,307 | 84.69% | 41 |
| 2023 Q3 | $709,803,792 | $535,567,910 | +$79,827,117 | 75.0% | 45 |
| 2023 Q2 | $610,911,952 | $378,751,579 | -$2,520,238 | 61.77% | 41 |
| 2023 Q1 | $623,666,127 | $401,644,918 | +$18,976,107 | 63.93% | 44 |
| 2022 Q4 | $622,846,458 | $239,898,646 | -$41,611,016 | 38.23% | 35 |
| 2022 Q3 | $580,552,458 | $262,269,316 | +$1,575,782 | 44.15% | 33 |
| 2022 Q2 | $594,504,458 | $253,628,177 | -$25,432,130 | 40.87% | 34 |
| 2022 Q1 | $625,412,958 | $310,645,005 | +$309,619,000 | 47.62% | 36 |